Targeting gene fusions in non-small cell lung cancer-a ceaseless success story?
Source : https://tlcr.amegroups.org/article/view/75976/html
Targeting gene fusions in non-small cell lung cancer-a ceaseless success story?
Conclusions/Relevance: Decision making on optimal targeted therapy in cases with rarer fusion events may be even more challenging due to limited clinical data. Moreover, for all targetable gene fusion events in NSCLC, we need to take the geographical aspect into account, which likely impacts preference and availability of specific targeted...
RET-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37627175/
RET alterations, such as fusions or mutations, drive the growth of multiple tumor types. These alterations are found in canonical (lung and thyroid) and non-canonical (e.g., gastrointestinal, breast, gynecological, genitourinary,...
Conclusions and Future Directions: RET fusions and RET activating mutations are therapeutically actionable oncogenic drivers which can be effectively targeted by novel and potent inhibitors selectively targeting the RET kinase. Deep and durable responses have been demonstrated both with selpercatinib and pralsetinib across a...
Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37655205/
This study was registered at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04280081) ClinicalTrials.gov Identifier: NCT04280081.
Conclusion: The study demonstrated favorable PROs in Chinese patients with RET fusion-positive NSCLC, TC, and RET-mutant MTC treated with selpercatinib. HRQoL was improved or stable as assessed by EORTC QLQ-30.
Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment with Small Molecule Inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37597577/
This single-institutional analysis reports survival outcomes of 116 patients with advanced thyroid cancer on targeted therapies, including 18 patients with brain metastases. Mutation-directed therapy for BRAF V600E mutations, RET mutations,...
Conclusions: This single-institutional analysis reports survival outcomes of 116 patients with advanced thyroid cancer on targeted therapies, including 18 patients with brain metastases. Mutation-directed therapy for BRAFV600E mutations, RET mutations, RET fusions, and NTRK fusions had superior survival.
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis - Investigational New Drugs
Source : https://link.springer.com/article/10.1007/s10637-023-01390-3
Background Rearranged during transfection (RET) fusion-positive occurs in approximately 2% of non-small cell lung cancer (NSCLC). This mutation often predicts metastasis risk and poor prognosis, and current mainstream therapies provide...
Conclusions: Selective RET inhibitors Pralsetinib and Selpercatinib have shown a good effect on RET fusion-positive NSCLC, with a low incidence of adverse events.